Valacyclovir-associated neurotoxicity among patients on hemodialysis and peritoneal dialysis: A nationwide population-based study
Front Med (Lausanne). 2022 Sep 20;9:997379. doi: 10.3389/fmed.2022.997379. eCollection 2022.ABSTRACTWhether valacyclovir-associated neurotoxicity (VAN) occurs more frequently in patients with end-stage renal disease (ESRD) on dialysis is unknown. This is the first population-based study to examine the risk of VAN associated with ESRD patients on dialysis. Among 2,284,800 patients diagnosed as having herpes zoster from 2002 to 2016, patients with ESRD on dialysis and individuals with normal renal function were enrolled in this study. Following propensity score matching, we compared the risk of altered mental status between ...
Source: Herpes - October 7, 2022 Category: Infectious Diseases Authors: Yi-Chun Wang Shu-Hui Juan Ching-Hao Li Chu-Lin Chou Li-Ying Chen Li-Nien Chien Te-Chao Fang Source Type: research
Kaposi Varicelliform Eruption With Contact Dermatitis in a Person Living with AIDS
Int J STD AIDS. 2022 Sep 15:9564624221127072. doi: 10.1177/09564624221127072. Online ahead of print.ABSTRACTKaposi varicelliform eruption (KVE) is a cutaneous dissemination of a viral infection, which is mostly caused by herpes simplex virus (HSV) in the setting of certain underlying skin diseases. KVE occurs mainly in infants and children, but very rarely in adults. Here, we report a case of KVE with contact dermatitis in a 36-year-old man with acquired immunodeficiency syndrome (AIDS), who was referred to our deparment with pruritic well-defined facial erythema and multiple vesicular lesions. A punch biopsy and immunohis...
Source: Herpes - September 16, 2022 Category: Infectious Diseases Authors: Liu Feng Yuan Tian Wei Zhao Li Wei Ran Kun Yang Yan Wu Wen Hui Lun Source Type: research
Kaposi Varicelliform Eruption With Contact Dermatitis in a Person Living with AIDS
Int J STD AIDS. 2022 Sep 15:9564624221127072. doi: 10.1177/09564624221127072. Online ahead of print.ABSTRACTKaposi varicelliform eruption (KVE) is a cutaneous dissemination of a viral infection, which is mostly caused by herpes simplex virus (HSV) in the setting of certain underlying skin diseases. KVE occurs mainly in infants and children, but very rarely in adults. Here, we report a case of KVE with contact dermatitis in a 36-year-old man with acquired immunodeficiency syndrome (AIDS), who was referred to our deparment with pruritic well-defined facial erythema and multiple vesicular lesions. A punch biopsy and immunohis...
Source: Herpes - September 16, 2022 Category: Infectious Diseases Authors: Liu Feng Yuan Tian Wei Zhao Li Wei Ran Kun Yang Yan Wu Wen Hui Lun Source Type: research
Incidence, risk factors, and consequences of human alphaherpesvirus infections in patients with psoriasis who initiate methotrexate or biologic agents
CONCLUSIONS: The incidence and risk of alphaherpesvirus infections was comparable between patients on MTX and TNFα inhibitors, while use of IL-17 inhibitors was associated with a lower risk.PMID:36097341 | DOI:10.1093/infdis/jiac367 (Source: Herpes)
Source: Herpes - September 13, 2022 Category: Infectious Diseases Authors: Omid Rezahosseini Mie Sylow Liljendahl Nikolai Loft Dina Leth M øller Zitta Barrella Harboe Mads Kirchheiner Rasmussen Kawa Khaled Ajgeiy Alexander Egeberg Lone Skov Susanne Dam Nielsen Source Type: research
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model
CONCLUSION: Valacyclovir showed comparable activity to donepezil and thus can be further researched for the treatment of Alzheimer's disease.PMID:36089794 | DOI:10.2174/1567202619666220908125125 (Source: Herpes)
Source: Herpes - September 12, 2022 Category: Infectious Diseases Authors: Parmi Patel Khushboo Faldu Ankit Borisa Hardik Bhatt Jigna Shah Source Type: research
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model
CONCLUSION: Valacyclovir showed comparable activity to donepezil and thus can be further researched for the treatment of Alzheimer's disease.PMID:36089794 | DOI:10.2174/1567202619666220908125125 (Source: Current Neurovascular Research)
Source: Current Neurovascular Research - September 12, 2022 Category: Neurology Authors: Parmi Patel Khushboo Faldu Ankit Borisa Hardik Bhatt Jigna Shah Source Type: research
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model
CONCLUSION: Valacyclovir showed comparable activity to donepezil and thus can be further researched for the treatment of Alzheimer's disease.PMID:36089794 | DOI:10.2174/1567202619666220908125125 (Source: Herpes)
Source: Herpes - September 12, 2022 Category: Infectious Diseases Authors: Parmi Patel Khushboo Faldu Ankit Borisa Hardik Bhatt Jigna Shah Source Type: research
Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model
CONCLUSION: Valacyclovir showed comparable activity to donepezil and thus can be further researched for the treatment of Alzheimer's disease.PMID:36089794 | DOI:10.2174/1567202619666220908125125 (Source: Current Neurovascular Research)
Source: Current Neurovascular Research - September 12, 2022 Category: Neurology Authors: Parmi Patel Khushboo Faldu Ankit Borisa Hardik Bhatt Jigna Shah Source Type: research
34767 Kombucha-induced irritant contact dermatitis
A 30-year-old woman presented with a 2-month history of an intermittent rash on the bilateral upper cutaneous lip. Rash was originally thought to be early herpes simplex, but was unresponsive to a 7-day course of valacyclovir. Patient noted the rash to appear during periods of increased consumption of kombucha, a fermented tea. She had only been applying petrolatum to the area. She had no history of atopy, and no significant medical history. She worked in a hospital without any significant occupational exposures. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - September 1, 2022 Category: Dermatology Authors: Catherine C. Motosko, Michael Abrouk Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Skinmed - August 17, 2022 Category: Dermatology Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Herpes - August 17, 2022 Category: Infectious Diseases Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Skinmed - August 17, 2022 Category: Dermatology Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Skinmed - August 17, 2022 Category: Dermatology Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Skinmed - August 17, 2022 Category: Dermatology Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series
We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed...
Source: Skinmed - August 17, 2022 Category: Dermatology Authors: Alexandra Monastirli Efstathia Pasmatzi George Badavanis Gianna Panagiotopoulou Assimina Apostolidou Dionysios Tsambaos Source Type: research
